Bile Acid Malabsorption
16
5
5
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
6.3%
1 terminated out of 16 trials
90.0%
+3.5% vs benchmark
44%
7 trials in Phase 3/4
44%
4 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (16)
Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
Probiotic in Patients With Bile Acid Malabsorption/Diarrhea
Magnesium in Gastrointestinal Disease
Treatment of Bile Acid Diarrhoea With Atorvastatin
Serum Metabolics-based Method for Diagnosing Bile Acid Diarrhoea
Bile Acids and Microbiome in Early Colorectal Carcinogenesis
Double-blind, Randomised Study of A3384 in BAM/BAD
Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)
A Study of Colesevelam in Fecal Incontinence
Impact of Foods on Bile Acids, Metabolites, and Inflammation
Effect of the Sequestrant Colesevelam in Bile Acid Diarrhoea
Treatment of Bile Acid Malabsorption With Liraglutide
Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy
Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption
Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea
Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease